Following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme. The timelines for this appraisal are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course.
Status | Suspended |
Decision | Selected |
Process | TA |
ID number | 1444 |
Project Team
Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
External Assessment Group | Warwick Evidence, Warwick Medical School, University of Warwick |
Stakeholders
Companies sponsors | Celgene, a BMS company (Lisocabtagene maraleucel) |
Others | Department of Health and Social Care |
NHS England | |
Welsh Government | |
Patient carer groups | Blood Cancer UK |
Leukaemia Care | |
Lymphoma Action | |
Professional groups | Association of Cancer Physicians |
British Society for Haematology | |
Cancer Research UK | |
Royal College of Pathologists | |
Royal College of Physicians | |
Royal College of Radiologists | |
Comparator companies | Pfizer (cytarabine, epirubicin) (confidentiality agreement signed, participating) |
Servier Laboratories (pixantrone) (confidentiality agreement signed, participating) | |
Accord Healthcare (carboplatin, cisplatin, cytarabine, epirubicin, etoposide, gemcitabine) (confidentiality agreement not signed, not participating) | |
Advanz Pharma (dexamethasone) (confidentiality agreement not signed, not participating) | |
Aspen (dexamethasone) (confidentiality agreement not signed, not participating) | |
Baxter Healthcare (ifosfamide) (confidentiality agreement not signed, not participating) | |
Cheplapharm Arzneimittel GmbH (etoposide) (confidentiality agreement not signed, not participating) | |
Consilient Health (carboplatin, dexamethasone) (confidentiality agreement not signed, not participating) | |
Glenmark Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating) | |
Hameln Pharma (dexamethasone) (confidentiality agreement not signed, not participating) | |
Hospira UK (carboplatin, cisplatin, cytarabine, dexamethasone, gemcitabine) (confidentiality agreement not signed, not participating) | |
Jazz Pharmaceuticals UK (cytarabine) (confidentiality agreement not signed, not participating) | |
Martindale Pharma (dexamethasone) (confidentiality agreement not signed, not participating) | |
medac GmbH (epirubicin, etoposide) (confidentiality agreement not signed, not participating) | |
Mylan (epirubicin) (confidentiality agreement not signed, not participating) | |
Napp Pharmaceuticals (rituximab) (confidentiality agreement not signed, not participating) | |
Panpharma UK (dexamethasone) (confidentiality agreement not signed, not participating) | |
Sun Pharmaceutical (gemcitabine) (confidentiality agreement not signed, not participating) | |
Roche Products (rituximab) (confidentiality agreement not signed, not participating) | |
Rosemont Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating) | |
Sandoz (cisplatin, rituximab) (confidentiality agreement not signed, not participating) | |
Thame Laboratories (dexamethasone) (confidentiality agreement not signed, not participating) | |
Wockhardt UK (dexamethasone) (confidentiality agreement not signed, not participating) | |
General commentators | All Wales Therapeutics and Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare products Regulatory Agency | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee | |
Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
09 November 2021 | Suspended. Following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme. The timelines for this appraisal are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course. |
27 July 2021 | The appraisal was discussed by the technology appraisal committee on 13 July 2021. The Committee for Medicinal Products for Human Use (CHMP) has not yet given its opinion on lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. We are therefore unable to release the committee’s recommendation. |
13 July 2021 | Committee meeting: 1 |
07 January 2021 | The Department for Health and Social Care has asked NICE to conduct an appraisal of lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Please note that following a regulatory update from the company, the timelines for this appraisal have been revised and technical engagement is now anticipated to begin in late April 2021. |
31 July 2020 | Invitation to participate |
12 June 2020 - 10 July 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
27 May 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies. Please note that following on from communications with the company , the timelines for this appraisal have now been confirmed. The appraisal is anticipated to begin during late July 2020 when we will write to you about how you can get involved. |
31 October 2019 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies. Please note that following on from advice received from the company further information regarding the timelines of this appraisal will be available in due course. |
29 May 2019 - 26 June 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
10 May 2019 | In progress. Referred 24 April 2017 |
For further information on our processes and methods, please see our CHTE processes and methods manual